Abstract:

BACKGROUND: Due to the hepatotoxicity induced by immunosuppressant, renal transplantation patients have high incidence of hepatic dysfunction. When they clinically have hepatic dysfunction, they are in need for hepatic protection treatment. However, the concentration of immunosuppressant must be monitored when hepatinica is added.
OBJECTIVE: To explore the effect of the combination of tacrolimus and Wuzhi-capsule on tacrolimus concentration and blood biochemical changes in cases after renal transplantation.
METHODS: Retrospective analysis on the tacrolimus concentration, renal function and blood biochemical changes when one case renal transplantation patient took or stopped taking Wuzhi-capsule who regarded tacrolimus as the immunosuppressant. The patient performed hemodialysis due to chronic glomerulonephritis and chronic renal insufficiency in June 1998, and received renal transplantation at August 2008. Tacrolimus + mycophenolate + prednisone were adopted after transplantation. Hepatic function became abnormal at 4 months after transplantation, and bifendate was added, which was substitute by Wuzhi-capsule at July 25, 2010. The medication was stopped on July 29, 2010. 
RESULTS AND CONCLUSION: If the renal transplantation recipients took tacrolimus, their blood tacrolimus concentration uplifted from 5.3 ng/L to 24.7 ng/L and they were diagnosed with hyperkalemia; if not, their blood tacrolimus concentration reduced from 24.7 ng/L to 6.1 ng/L and their potassium dropped from 6.4 mmol/L to 4.6 mmol/L. Stable renal transplantation recipients must have their tacrolimus blood concentration, liver and kidney function, as well as electrolytes monitored after adding Wuzhi-capsule; moreover, they should adjust the tacrolimus dosage timely so as to protect renal graft function.